Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › H2020

Tremipen · The first simple monitoring device for Parkinson and other Tremor diseases

H2020Status: CLOSED1 December 201731 March 2018EU funding €50,000Call H2020-SMEInst-2016-2017

Many health conditions like diabetes or hypertension have simple measurement devices. However, there is no equivalent for Parkinson´s Disease (PD) or Essential Tremor (ET), making an accurate clinical diagnosis and follow-up of these diseases a challenge. Instead, current check-ups and diagnosis of PD/ET are mostly carried out using subjective methods based simply on observation during visits (every 6 months). Even though there are some traditional solutions for Tremor monitoring, such as Electromyography or accelerometers, these are large devices which are expensive, take long time to use and provide no direct information for the patient, and though new solutions are being developed (such as 24h devices or phone apps), these are not 100% accurate, nor certified for their medical use. Moreover, none of the existing/developing solutions consider the psychological affection of patients, who feel helpless exposed to the disease and often suffer depressions. Our goal with Tremipen is to offer the first simple, small, easy-to-use, reliable and cost-effective device for PD and ET home-monitoring: a pen-like device, which just needs to be held for 60 seconds a day, to register the amplitude of the tremors. This information (which is shown in a display for the patients to see) is also stored for the subsequent analysis of doctors (with a tailored software), enabling a monitoring of the disease between visits. In this way, Tremipen does not aim to substitute doctors, but to act as a tool to help monitoring and treatment, while promoting patients´ empowerment and improving patients’ life quality for the over 10 million patients of PD/ET worldwide.Moreover, through this project we aim to boost the growth and competitiveness of our company: Early forecast predict sales of over 26,000 units 3 years after commercialization, resulting in €10.1 Million of accumulated profit.

Consortium · 1 organisation

coordinator

TREMITAS GMBH

AT · €50,000

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.